ArticleFrontiers in pharmacology2026
Clinical efficacy of comprehensive traditional Chinese medicine in adjuvant therapy for stage Ib-IIIa resected non-small cell lung cancer: a multi-center, randomized, double-blind, placebo-controlled trial.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrence and metastasis after radical resection for non-small cell lung cancer (NSCLC) remain a significant cause of treatment failure. Comprehensive Traditional Chinese Medicine (TCM) has emerged as a vital therapeutic approach in China. This study evaluated the efficacy and safety of TCM treatment with platinum-based adjuvant chemotherapy for patients of stage IB-IIIA resected NSCLC. Methods: A randomised controlled trial was conducted at four centres in Shanghai, China. A total of 286 participants with completely resected (R0) stage IB-IIIA NSCLC were randomly divided in a 1:1 ratio to a TCM treatment group (n = 143) and a control group (n = 143). Which received adjuvant chemotherapy plus TCM granules or placebo granules, for four cycles. And then, followed by four cycles of Huachansu injections. The received in addition to the adjuvant chemotherapy, followed by placebo injections. Results: ITT analysis was concluded with 286 patients. 2-year disease-free survival (DFS) rate (95% Confidence Interval [CI]) was 65.70% (57.86, 73.54) in the TCM treatment group and was 55.4% (47.17, 63.63) in the control group, the difference was not statistically significant, but a trend was observed (p = 0.08). A significantly prolonged DFS in the TCM group was revealed in contrast to the control group (37.8 months vs. 31.6 months, Hazard Ratio [HR], 0.73; 95% CI 0.579, 0.995; p = 0.045). TCM granules significantly improved lung cancer-related symptoms including fatigue, pain, dyspnea, insomnia, cough, chest pain and diarrhea, and promote physical function, emotional function and overall health. No unexpected treatment-related adverse events were observed in both groups. Conclusion: Comprehensive Traditional Chinese Medicine treatment combined with chemotherapy-based adjuvant therapy have a positive impact on DFS and improved quality of life in NSCLC patients. These findings suggested that TCM can be used as one of the adjuvant therapies following unselected radical resection in Chinese patients with stage IB-IIIA NSCLC. Clinical Trial Registration: https://www.chictr.org.cn/, identifier ChiCTR-IPR-16009062.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.